维得利珠单抗治疗溃疡性结直肠炎效果及对Th22细胞亚群、肠黏膜屏障功能的影响

The effect of vederizumab on ulcerative colitis and its influence on Th22 cell subsets and intestinal mucosal barrier function

[目的]探究维得利珠单抗在溃疡性结直肠炎患者中的治疗效果及对Th22细胞亚群、肠黏膜屏障功能的影响。[方法]选取86例溃疡性结直肠炎患者,使用随机数字表将患者分为观察组(n=43)与对照组(n=43)。对照组患者采取口服美沙拉嗪肠溶片治疗,观察组在对照组基础上联合使用维得利珠单抗。比较2组患者的临床疗效、炎症指标、Th22细胞亚群、肠黏膜屏障功能及安全性。[结果]观察组治疗有效率(93.02%)明显高于对照组(72.09%),观察组与对照组患者临床疗效比较差异有统计学意义(P<0.05);2组患者的Th22细胞亚群、白细胞介素-6(IL-6)、抗肿瘤坏死因子-α(TNF-α)、白细胞介素-23(IL-23)及降钙素原(PCT)水平均明显降低,观察组显著低于对照组;2组患者的D-乳酸、尿乳果糖/甘露醇(L/M)、二胺氧化酶(DAO)及内毒素(ET)均明显降低,观察组低于对照组,2组比较差异有统计学意义(P<0.05);2组不良反应总发生率比较差异无统计学意义(P>0.05)。[结论]维得利珠单抗对溃疡性结直肠炎患者的疗效显著,有效降低炎症水平,改善肠道黏膜屏障功能,安全性较高,具有临床实用价值。

[Objective]To investigate the therapeutic efficacy of vderizumab in patients with ulcerative colitis and its effect on Th22 cell subsets and intestinal barrier function.[Methods]Eighty-six patients with ulcerative colitis were randomly divided into observation group(n=43)and control group(n=43).Patients in the control group were treated with mesalazine enteric-coated tablets,while patients in the observation group were treated with vederizumab in addition to the control group treatment.The clinical efficacy,inflammatory index,Th22 cell subsets,intestinal mucosal barrier function and safety were compared between the two groups.[Results]After treatment,there was a significant difference between the two groups(P<0.05).The effective rate in the observation group(93.02%)was significantly higher than that in the control group(72.09%).The levels of Th22,IL-6,Il-23,TNF-αand PCT in the two groups were significantly lower than those in the control group(P<0.05).D-lactic acid,L/M,DAO and ET in the observation group were significantly lower than those in the control group(P<0.05),and the total incidence of adverse reactions was not significantly different between the two groups(P>0.05).[Conclusion]Vedozumab is effective and safe in the treatment of patients with ulcerative colitis,which can effectively reduce the level of inflammation and improve the intestinal mucosal barrier function.